Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma
Marked tumor reduction was confirmed in 62.5% of patients with pembrolizumab plus cisplatin and 5-fluorouracil with less adverse events. This regimen could be administered as induction chemotherapy for patients with T4b ESCC.
Authors
- Yusuke Suzuki (ORCID: https://orcid.org/0000-0001-9357-4852)
- Masahiro Horikawa (ORCID: https://orcid.org/0000-0003-1664-2676)
- Shinya Kaneshiro
- Shinya Kodashima (ORCID: https://orcid.org/0000-0002-3125-317X)
- Takashi Kiyokawa (ORCID: https://orcid.org/0000-0002-7899-7731)
- Takeo Fukagawa (ORCID: https://orcid.org/0000-0002-9425-3767)
- Yuko Sasajima (ORCID: https://orcid.org/0000-0002-6972-3843)
- Takatsugu Yamamoto (ORCID: https://orcid.org/0000-0001-7425-823X)
- Yasutoshi Oshima
- Kenshiro Shiraishi (ORCID: https://orcid.org/0000-0002-2295-517X)
- Nobukazu Hokamura (ORCID: https://orcid.org/0000-0002-9717-7464)
- Naruyoshi Soeda
- Koichiro Abe (ORCID: https://orcid.org/0000-0002-2577-2977)
- Ai Ito (ORCID: https://orcid.org/0000-0003-4662-6415)
- Akihiro Nomoto (ORCID: https://orcid.org/0000-0003-1353-096X)
- Ryoji Fukushima
- Tsuyoshi Ishida
Institutions
- Teikyo University (JP)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1186/s12876-024-03382-w
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.57